Page last updated: 2024-11-06

divaplon

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

divaplon: structure given in UD [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65822
CHEMBL ID281164
SCHEMBL ID678101
MeSH IDM0168576

Synonyms (22)

Synonym
divaplon
CHEMBL281164
(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)-phenylmethanone
6-ethyl-7-methoxy-5-methylimidazo(1,2-a)pyrimidin-2-yl phenyl ketone
unii-4aov43246g
methanone, (6-ethyl-7-methoxy-5-methylimidazo(1,2-a)pyrimidin-2-yl)phenyl-
divaplonum
divaplon [inn]
divaplonum [inn-latin]
90808-12-1
4aov43246g ,
divaplone [inn-french]
divaplone
SCHEMBL678101
ru-32698
DTXSID40238269
Q5283825
methanone,(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)phenyl-
divaplon; ru 32698;dru32698
(6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)(phenyl)methanone
methanone, (6-ethyl-7-methoxy-5-methylimidazo[1,2-a]pyrimidin-2-yl)phenyl-
AKOS040748262
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (18)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.507510.0000AID40834
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.507510.0000AID40834
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.507510.0000AID40834
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.505710.0000AID40834
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.05600.00031.38338.4000AID40834
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.497310.0000AID40834
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.507510.0000AID40834
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.498810.0000AID40834
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.504610.0000AID40834
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.507510.0000AID40834
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.507510.0000AID40834
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.507510.0000AID40834
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.506510.0000AID40834
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.505710.0000AID40834
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.507510.0000AID40834
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.05600.00040.16800.9772AID40834
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.507510.0000AID40834
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)0.05600.00010.507510.0000AID40834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID114042Muscle relaxation in mice by using Pull-Up test1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics.
AID113780Anticonvulsant activity in CD-1 mice with 120 mg/kg of leptazol1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics.
AID185195Minimum Effective Dose (MED) was measured using Food-Conflict test in rats1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics.
AID396085Displacement of [3H]flunitrazepam from benzodiazepine receptor in rat forebrain2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
3D and quantum QSAR of non-benzodiazepine compounds.
AID114234Sedative/muscle relaxant effect in mice by using Rotating-Drum test1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics.
AID184854Minimum Effective Dose(MED was measured by using Licking-Conflict test in rats1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics.
AID40834Inhibition of 0.6 nM [3H]flunitrazepam binding to GABA-A central benzodiazepine receptor of rat forebrain membrane1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
(Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's3 (42.86)18.2507
2000's2 (28.57)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]